The FDA approved expanded adjuvant therapy options for adults with renal cell carcinoma with a clear cell component who are at intermediate-high or high risk of recurrence after nephrectomy, with or without...
In an international Bayesian adaptive RCT of adults with MSSA bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin for 90-day all-cause mortality and was associated with less acute kidney...
The FDA approved tebipenem pivoxil (Utebzi) for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options.
Several sessions at the 2026 American Association of Nurse Practitioners National Conference in Las Vegas, NV, will address migraine-related diagnosis, treatment, red flags, and care considerations across...
ACOG’s 2026 maternal immunization schedule outlines vaccine recommendations before, during, and after pregnancy, including influenza, COVID-19, Tdap, and RSV vaccination.
In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.
The FDA approved Baxfendy as an adjunctive treatment to lower blood pressure in adults with hypertension not adequately controlled on other antihypertensive medications.
On May 22, 2026, the FDA approved datopotamab deruxtecan-dlnk for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy, based on...
